Teva Expands Central Nervous System (CNS) Development Pipeline with Acquisition of Huntexil® Development Program Rights from

  Teva Expands Central Nervous System (CNS) Development Pipeline with
  Acquisition of Huntexil® Development Program Rights from NeuroSearch A/S

  Drug candidate to be assessed for managing voluntary motor disturbances in
                              Huntington disease

Business Wire

JERUSALEM -- September 27, 2012

Teva Pharmaceutical Industries Ltd (NYSE: TEVA) announced today that it has
concluded an Asset Transfer Agreement with NeuroSearch A/S of Denmark (OMX:
NEUR) to purchase all rights, assets and obligations relating to Huntexil®
(pridopidine / ACR16), a drug candidate being developed for the symptomatic
treatment of hand movement, balance and gait disturbances in Huntington
disease (HD). Under the agreement, Teva will pay to NeuroSearch approximately
$26 million (DKK 150 million) over a period of at least six months. Regulatory
and commercialization milestone payments may result in additional funding for
NeuroSearch.

Previous trials in the US, EU and Canada demonstrated significant symptomatic
relief for patients with HD including improved hand movements and improved
gait and balance. These results were observed without any side effects such as
sedation and depression seen with other therapies such as neuroleptics and
tetrabenazine. Teva believes that Huntexil® will, used as a symptomatic agent,
make a real difference to the quality of life for patients suffering from HD.

“Based on the clinical trial evidence to date, we believe Huntexil® holds
promise for symptomatic relief for HD and merits additional study in
late-stage clinical development,” commented Michael R. Hayden, M.D., Ph.D.,
one of the world’s leading experts on Huntington disease and President of
Global R&D and Chief Scientific Officer of Teva Pharmaceutical Industries Ltd.
“Teva has a broad commitment to find new approaches to managing devastating
CNS diseases, such as Huntington disease. This promising development for Teva
is just one example of our covenant with patients to develop medicines to
improve their quality of life all around the world.”

Huntexil® Development Program

Huntexil® (pridopidine / ACR16) is an oral small molecule dopamine D2
stabilizer being developed for the symptomatic treatment of non-choreic motor
disorders, including for Huntington disease (HD). Huntington disease affects
about one person in 10,000 in North America and Europe and generally results
in death within 15 to 25 years of diagnosis.

Teva intends to design and complete new clinical studies of Huntexil® to
assess its potential for symptomatic relief of HD. Advanced-stage clinical
studies of Huntexil® conducted in the US, EU and Canada in patients with HD
demonstrated a significant treatment effect on Total Motor Score [TMS]), but
failed to meet the primary endpoint (Modified Total Motor score [mTMS]). Data
from the clinical studies were presented to the FDA and EMA in the first half
of 2011, but were found insufficient to file for marketing approval.

About Huntington disease

Huntington disease (HD),is a fatal neurodegenerative disease characterized by
uncoordinated and uncontrollable movements, cognitive deterioration, and
behavioral and/or psychological problems. The classic onset of HD symptoms
typically occurs in middle age, but the disease also manifests in children and
the elderly. Disease progression is characterized by a gradual decline in
motor control, cognition, and mental stability and generally results in death
within 15‐25 years of clinical diagnosis.

HD is a genetic disease, transmitted via autosomal‐dominant inheritance. The
defective gene, found on chromosome 4, causes the production of a mutant
protein, huntingtin, which aggregates in the central nervous system (CNS) and
results in the pathogenesis of HD. The prevalence of HD is approximately 10
per 100,000 in the US and Europe. The only currently marketed product in the
US indicated for HD is tetrabenazine, which has no effect on non‐choreic
symptoms and disease progression, which remain as significant unmet medical
needs; also, tetrabenazine is associated with serious side effects such as
suicidality and depression.

About Teva Pharmaceutical Industries Ltd

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic drugs as
well as innovative and specialty pharmaceuticals and active pharmaceutical
ingredients. Headquartered in Israel, Teva is the world's leading generic drug
maker, with a global product portfolio of more than 1,300 molecules and a
direct presence in about 60 countries. Teva's branded businesses focus on CNS,
oncology, pain, respiratory and women's health therapeutic areas as well as
biologics. Teva currently employs approximately 46,000 people around the world
and reached $18.3 billion in net revenues in 2011.

Teva's Safe Harbor Statement under the U. S. Private Securities Litigation
Reform Act of 1995: The following discussion and analysis contains
forward-looking statements, which express the current beliefs and expectations
of management. Such statements involve a number of known and unknown risks and
uncertainties that could cause our future results, performance or achievements
to differ significantly from the results, performance or achievements
expressed or implied by such forward-looking statements. Important factors
that could cause or contribute to such differences include risks relating to:
our ability to develop and commercialize additional pharmaceutical products,
(including the development Huntexil® (pridopidine / ACR16), competition from
the introduction of competing generic equivalents and due to increased
governmental pricing pressures, the effects of competition on sales of our
innovative medicines, especially Copaxone® (including competition from
innovative orally-administered alternatives as well as from potential generic
equivalents), potential liability for sales of generic medicines prior to a
final resolution of outstanding patent litigation, including that relating to
our generic version of Protonix®, the extent to which we may obtain U.S.
market exclusivity for certain of our new generic medicines, the extent to
which any manufacturing or quality control problems damage our reputation for
high quality production and require costly remediation, our ability to
identify, consummate and successfully integrate acquisitions (including the
acquisition of Cephalon), our ability to achieve expected results through our
innovative R&D efforts, dependence on the effectiveness of our patents and
other protections for innovative medicines, intense competition in our
specialty pharmaceutical businesses, uncertainties surrounding the legislative
and regulatory pathway for the registration and approval of
biotechnology-based medicines, our potential exposure to product liability
claims to the extent not covered by insurance, any failures to comply with the
complex Medicare and Medicaid reporting and payment obligations, our exposure
to currency fluctuations and restrictions as well as credit risks, the effects
of reforms in healthcare regulation and pharmaceutical pricing and
reimbursement, adverse effects of political instability and adverse economic
conditions, major hostilities or acts of terrorism on our significant
worldwide operations, increased government scrutiny in both the U.S. and
Europe of our agreements with brand companies, interruptions in our supply
chain or problems with our information technology systems that adversely
affect our complex manufacturing processes, the impact of continuing
consolidation of our distributors and customers, the difficulty of complying
with U.S. Food and Drug Administration, European Medicines Agency and other
regulatory authority requirements, potentially significant impairments of
intangible assets and goodwill, potential increases in tax liabilities
resulting from challenges to our intercompany arrangements, the termination or
expiration of governmental programs or tax benefits, any failure to retain key
personnel or to attract additional executive and managerial talent,
environmental risks, and other factors that are discussed in our Annual Report
on Form 20-F for the year ended December 31, 2011, in this report and in our
other filings with the U.S. Securities and Exchange Commission (“SEC”).
Forward-looking statements speak only as of the date on which they are made,
and we undertake no obligation to update any forward-looking statements or
other information contained in this report, whether as a result of new
information, future events or otherwise. You are advised, however, to consult
any additional disclosures we make in our reports to the SEC on Form 6-K. Also
note that we provide a cautionary discussion of risks and uncertainties under
“Risk Factors” in our Annual Report on Form 20-F for the year ended December
31, 2011. These are factors that we believe could cause our actual results to
differ materially from expected results. Other factors besides those listed
could also adversely affect us. This discussion is provided as permitted by
the Private Securities Litigation Reform Act of 1995.

Contact:

Teva Pharmaceutical Industries Ltd
IR:
United States
Kevin C. Mannix, 215-591-8912
or
Joseph Marczely, 267-468-4281
or
Israel
Tomer Amitai, 972 (3) 926-7656
or
PR:
Israel
Hadar Vismunski-Weinberg, 972 (3) 926-7687
or
United States
Denise Bradley, 215-591-8974
 
Press spacebar to pause and continue. Press esc to stop.